Latest News

By Meghan McCarthy 

What is one quality that makes you great?

For many, this question can be a difficult to answer. Traditional societal values often discourage openly complimenting oneself in public. Yet, Jean Haskell, facilitator of the Penn Memory Center’s Cognitive Comedy class, often begins sessions by posing this very question.

As I observed a fall class, I was struck by the ease and comfort with which participants responded.

“I try to be kind,” one participant said.
“I work out every other day,” another shared.
“I am great because of my wife,” a third added.

This seemingly simple question revealed a profound impact. It’s a question we might all benefit from asking more often. 

It has been yet another groundbreaking year for research in Alzheimer’s disease and related dementias (ADRDs). At the Penn Memory Center (PMC), we asked team members to reflect on the most impactful initiatives and publications from 2024.  

By Meghan McCarthy 

Author’s Note: This article is part of ongoing coverage of the 2024 Alzheimer’s Association International Conference (AAIC). To view all highlights, please click here. 

Recent research through the Departments of Bioengineering, Neurology, and Radiology at the University of Pennsylvania is exploring the biologic causes for atypical Alzheimer’s disease (AD). Led by Lasya Sreepada, MS, BS, a doctoral candidate at Penn’s School of Engineering and Applied Sciences, the team presented their work at the 2024 AAIC.

Atypical AD affects approximately 15 percent of AD patients. The term encompasses individuals who experience cognitive outcomes that differ from typical AD symptoms. For example, individuals with atypical AD may experience greater change in their behavior, personality, and language compared to symptoms predominantly based around memory. Usually, atypical AD patients also develop their symptoms at a younger age.

Atypical AD highlights the heterogeneity in Alzheimer’s disease and related dementias (ADRD), or the variance in disease symptoms and presentation.  

Sreepada’s work aims to understand ADRD heterogeneity. 

Lasya Sreepada

By Meghan McCarthy  

Bianca Cavedoni-Urbano, MD, has always dreamt of becoming a physician. While she cannot pinpoint the exact moment her dream began, providing care to patients has always felt like her calling. 

Her medical journey—from rigorous training, a move across the globe, and research engagements—has brought many changes. Yet, she has remained committed to her mission. 

Bianca Cavedoni-Urbano

Transitioning to American Training 

Born and raised in Venezuela, Dr. Cavedoni-Urbano attended la Universidad del Zulia for medical school. After completing residency in internal medicine, she was faced with a difficult decision. Due to the ongoing political crisis in Venezuela, she struggled to see opportunities for her ongoing success. 

“I did not have the resources to learn or do research,” Dr. Cavedoni-Urbano said. “My family was already abroad, so I decided to leave and come to the U.S.” 

Without knowing anyone, carving her own path in the United States took determination and courage. 

In addition to passing the required credentialling exams, Dr. Cavedoni-Urbano sought research training. Without a significant research background at that time, she accepted a volunteer position at New York University. Her bilingual background was a significant asset in her project, which focused on Alzheimer’s disease (AD) and sleep apnea. 

By Meghan McCarthy 

Editor’s Note: This article is part of the Disability and Dementia Series, which is an ongoing project aimed to highlight Alzheimer’s disease and related dementias (ADRD) experiences in individuals with intellectual disabilities.  

In a 2017 testimony to congress, advocate Frank Stephens stated: “I cannot tell you how much it means to me that my extra chromosome might lead to the answer to Alzheimer’s.” 

[Above: Video of Frank Stephens’ testimony]  

A powerful moment, Stephens’ message was clear. Individuals with Down syndrome (DS) must and should be included in Alzheimer’s disease research.  

It is estimated that over 50% of individuals with DS will develop Alzheimer’s disease (AD) as they age. To put it in perspective, approximately 11% of all adults aged 65 and older in the United States develop AD.  

Despite this, many disparities exist in standardized care and research inclusion methods for individuals with DS.  

Beth Wood Discusses the Evolution of Genetic Counseling Through Telehealth and Chatbots at AAIC 2024 

By Meghan McCarthy 

Author’s Note: This article is part of ongoing coverage of the 2024 Alzheimer’s Association International Conference (AAIC). To view all highlights, please click here.  

Elisabeth Wood, MS, LCGC, has been a genetic counselor at Penn Medicine since 2003. Originally working for the Center for Neurodegenerative Disease Research (CNDR), she spent over a decade focusing on genetic forms of dementias and related disorders. Currently, she works in the Penn Telegenetics Program, where she helps to conduct research on genetic counseling services via telehealth in both clinical and research settings.  

Wood sat down with Penn Memory Center (PMC) Staff Writer Meghan McCarthy to discuss her latest work using chatbots as an informational resource for individuals interested in or already receiving genetic counseling. She also presented her work at this year’s AAIC in Philadelphia.  

By Meghan McCarthy 

Author’s Note: This article is part of ongoing coverage of the 2024 Alzheimer’s Association International Conference (AAIC). To view all highlights, please click here.   

When Rafi walked into the Pennsylvania Convention Center, he was immediately taken by its sheer scale.  

Spanning over 2.1 million square-feet, the venue had large research posters hung throughout the exhibition space. Soft and loud sounds of bustling crowds filled hallways. Stages with prominent researchers and entertainment groups were broadcasted. A motif of purple and white adorned all spaces.  

With thousands of conference attendees, the 2024 Alzheimer’s Association’s International Conference convened researchers, clinicians, trainees, and families affected by Alzheimer’s disease and related dementias (ADRDs).  

Rafi was amongst the many care partners to take part in the event.  

By Meghan McCarthy 

Author’s Note: This article is part of ongoing coverage of the 2024 Alzheimer’s Association International Conference (AAIC). To view all highlights, please click here.  

Imagine a tiered, ornately decorated cake. Each tier has a unique flavor, filling, and frosting. The cakes are stacked at various heights and widths and adorned with décor. If you were to slice through each layer, you could distinctly identify each layer’s cake, filling, and frosting. While it would be possible to cut through all tiers together, you could appreciate and evaluate the flavors better by creating slices for the tiers singularly.

The process of analysis of brain donation is like cutting through and judging a multi-layered cake.

Penn Medicine and UC San Diego scientists will develop a tau-targeting drug candidate through IND-enabling studies

This illustration shows tau protein (red) becoming detached from a microtubule (blue). A new compound discovered by researchers at UC San Diego and University of Pennsylvania may be able to treat Alzheimer’s disease by normalizing microtubule structure and function. (Credit: Penn Today)

By Meagan Raeke, PennMedicine.org

A multidisciplinary team of scientists led by Kurt Brunden, Ph.D., at the University of Pennsylvania Perelman School of Medicine, and Carlo Ballatore, Ph.D., at University of California San Diego, has been awarded a $6.9 million grant from the National Institute on Aging (NIA) to prepare a potential disease-modifying Alzheimer’s treatment for future clinical trials. In a recently published study about the new compound, called CNDR-51997, the team found it was effective in restoring brain health in mouse models of Alzheimer’s disease. CNDR-51997 was identified through a joint drug discovery program at Penn and UC San Diego that was supported by grants from the NIA.

The new grant will help the researchers demonstrate the drug’s safety in formal studies required by the U.S. Food and Drug Administration (FDA) prior to the initiation of human testing. By the end of the three-year grant period, the researchers hope to submit an Investigational New Drug (IND) application to the FDA that, if approved, would allow for Phase 1 clinical studies.